3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Pathologic Complete Response
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Colonic Polyps
1
Adenomatous Polyposis Coli
1
Interventions
pertuzumab
1
cc-486
1
Trastuzumab
1
Sulindac
1
Magnetic Resonance Spectroscopy
1
Epirubicin
1
Docetaxel
1
Cytarabine
1
Carboplatin
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Pathologic Complete Response
×
Sulindac
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn